First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
Clinical trial NCT03881111 · WITHDRAWN
Trial details
- NCT number
- NCT03881111
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-21
- Primary completion
- 2021-05-11
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.